Serum free light-chain (FLC) concentrations were measured by a sensitive nephelometric immunoassay in 66 patients with AL amyloidosis before and after treatment with highdose melphalan and autologous stem cell transplantation (HDM/SCT). At 1 year after HDM/SCT, 27 patients (41%) achieved a complete hematologic response (CR), that is, disappearance of the monoclonal gammopathy previously evident by immunofixation electrophoresis (IFE) in serum and urine and of plasma cell clonality in the bone marrow. Abnormally elevated FLC levels became normal in 27 patients (41%), and decreased by 490% in 37 (56%). Average improvements in FLC were 94% for patients who achieved a CR and 72% for those who did not (P ¼ 0.0001). However, a reduction in FLC of 490% was associated with a similar high likelihood of clinical improvement and prolonged survival, whether or not patients achieved a CR. While CR, as defined by standard criteria, is a more stringent indicator of hematologic response than are decreases in abnormally elevated FLC levels per se, these measures of hematologic response are complementary, and decreases in FLC are more readily detected early after treatment than are the changes in IFE and marrow studies required to determine CR.
serum free light-chain assay AL amyloidosis is the most common form of systemic amyloidosis. In this disease fibrillar amyloid protein deposits in tissues are derived from circulating monoclonal immunoglobulin (Ig) light chains. Since the clonal plasma cell dyscrasias that cause this disease are typically low grade and often subtle, clinically meaningful hematologic responses to treatment are generally difficult to monitor quantitatively. 1 A circulating intact Ig paraprotein cannot be identified by serum or urine protein electrophoresis (SPEP or UPEP) at the time of diagnosis in more than half of patients with AL amyloidosis, 1 and in many others the concentration is so low that accurate quantification is not possible. Immunofixation electrophoresis (IFE) is more sensitive than SPEP or UPEP and can detect free monoclonal immunoglobulin light chains in the urine of 80-90% of patients, but IFE results are not quantitative. 2 Consequently, conventional immunochemical and electrophoretic techniques generally provide only qualitative measures of hematologic response to treatment in AL amyloidosis.
High-dose intravenous melphalan and stem cell transplantation (HDM/SCT) has replaced low-dose oral chemotherapy as first-line treatment for selected patients with AL amyloidosis during the past decade.
3 HDM/SCT has been shown to induce hematologic remissions and clinical improvement in a substantial proportion of patients who undergo this treatment. Moreover, HDM/SCT also prolongs survival and significantly improves the quality of life of selected patients. [4] [5] [6] Treatment outcomes in AL amyloidosis have been shown to depend on hematologic responses following treatment, that is, the extent to which the plasma cell dyscrasias and monoclonal light-chain gammopathies that underlie this disease are suppressed or eliminated. 3, 4 Several approaches have been used to define hematologic response following HDM/SCT and other forms of treatment. In our clinical studies, we have defined hematologic responses as either complete or incomplete. A hematologic complete response (CR) requires that there be no evidence of a persistent monoclonal gammopathy by IFE of serum and urine proteins, or of a persistent plasmacytosis or plasma cell clonality by bone marrow biopsy immunohistochemistry. 7 Achievement of a hematologic CR 1 year after HDM/SCT treatment is associated with significant survival benefits and clinical improvement in patients with AL amyloidosis. 4 Recently, quantitative serum free light-chain (FLC) measurements have been introduced as a new tool for following hematologic responses in AL amyloidosis, 8 and it has been reported that a 450% reduction in FLC levels following treatment predicts clinical benefit. 9 Here, in the present study, we have carried out a retrospective analysis of FLC measurements before and after HDM/SCT treatment and have correlated changes in these measurements with complete and incomplete hematologic responses as defined by standard criteria and with clinical outcome.
Materials and methods
Patients with AL amyloidosis undergoing HDM/SCT from 1994 to 2003 were studied with the approval of the Institutional Review Board of Boston University Medical Center. Serum samples were obtained from patients prior to and at 4 3 months after HDM/SCT. All serum samples were stored at À201C until used.
All patients had a histologic diagnosis of amyloidosis with evidence of a plasma cell dyscrasia and met eligibility criteria for HDM/SCT treatment in clinical protocols. Patients received 100-200 mg/m 2 intravenous melphalan followed by SCT 24-72 h after completion of chemotherapy. All patients were followed for hematologic and clinical responses at 3 and 6 months, and annually thereafter. At these visits, IFE of serum and urine was performed, and bone marrow biopsies for immunohistochemical analysis of plasma cell numbers and k and l light-chain expression were performed. Hematologic complete responses following (CR) treatment required a normalization of all these studies, as reported previously. 3, 4, 7 Serum and urine immunofixation electrophoresis (SIFE/ UIFE) were performed using the Sebia HYRYS (Sebia, Norcross, GA, USA) system. SIFE and UIFE were both run on the Sebia HYDRAGEL 4 IF using acid violet staining. The SIFE method has a detection limit of about 12.5-25 mg/dl. UIFE was run using the Sebia Bence Jones protocol, which detects both free and bound light chains and has a detection limit of about 1-2 mg/dl. Results were interpreted as positive if there was a single restricted band on the gel indicative of a monoclonal protein.
Serum FLC assays were performed using a latexenhanced immunoassay (Freelitet the Binding Site, San Diego, CA, USA) on a nephelometric analyzer, the Beckman Coulter Image Immunochemistry System (Beckman Coulter, Fullerton, CA, USA), on stored samples. This assay has a detection limit of about 0.3 and 0.4 mg/dl for k and l, respectively. The reference ranges for k and l FLC were 3.3-19.4 mg/l and 5.7-26.3 mg/l, respectively, and 0.26-1.65 for the k:l ratio. The serum FLC assay was performed prior to and 3 months to 5 years after HDM/ SCT, depending on the availability of stored serum samples. In each patient, the serum concentration of FLC after HDM/SCT was expressed as a percentage of the pretreatment value or normalization compared to pretreatment values. In patients with renal insufficiency or renal failure, the serum FLC ratio, rather than the concentration of FLC, after HDM/SCT was expressed as a percentage of the pretreatment value or normalization compared to pretreatment values. In both instances, it was recorded as FLC response after HDM/SCT.
All patients were followed for survival and for clinical improvement of the amyloid-related organ dysfunction, as reported previously. 3, 4 All deaths were classified as either related or unrelated to progressive amyloid disease.
Student's t-test was used to compare FLC responses in patients who achieved a hematologic CR vs those who did not. Means of FLC responses in the two groups were compared using a one-tailed analysis in Excel, assuming unequal variances.
Results and discussion
A total of 78 patients (49 male) were studied in this retrospective analysis. Their median age was 60 years (range, 37-74 years). A monoclonal protein was detected by high-resolution immunofixation in the serum and/or urine of all patients (64 l and 14 k). Serum FLC levels were abnormally elevated and informative in 66 patients (85%) prior to HDM/SCT, and these patients are included in the subsequent analysis. In all, 11 patients (15%) did not have abnormally elevated serum FLC levels prior to HDM/SCT, although they had clear evidence of an underlying plasma cell dyscrasia by other measures. The k or l class of monoclonal immunoglobulin demonstrated by the FLC assay was corroborated by immunofixation or bone marrow immunohistochemistry studies in all 66 patients.
Serum FLC assays were performed on serum samples obtained before and at varying times after HDM/SCT (median, 13.5 months; range, 3-60 months). The FLC became normal following HDM/SCT treatment in 27 patients (41%). In all, 37 patients (56%) had a greater than 90% reduction in FLC levels, and 58 patients (88%) had a greater than 50% reduction.
FLC responses for each patient are depicted graphically in Figure 1 . The mean improvement in FLC level was 94% for patients who achieved a hematologic CR by standard criteria and 72% for those who did not (P ¼ 0.0001, t-test).
A total of 27 patients (41%) experienced a hematologic CR following HDM/SCT. All these patients had a 450% reduction in serum FLC levels (Figure 1) , and 21 patients (78%) had a 490% reduction in FLC. Of the 39 (59%) patients who did not achieve a hematologic CR after HDM/SCT, 31 (79%) had 450% reduction in serum FLC levels ( Figure 1 ) and 14 (36%) had 490% reduction in FLC.
Of the 66 patients with interpretable, elevated FLC before treatment, 10 (15%) died at a median time of 55.5 months (range, 13-81 months) after HDM/SCT. Of these 10 patients, eight deaths were associated with progressive amyloid-related disease and organ dysfunction. One of these eight deaths occurred 5 years after HDM/SCT in a patient who had initially been found to have achieved a CR 1 year after treatment but who later relapsed. Among the 39 patients who did not achieve a CR, seven (18%) eventually died of progressive amyloid disease. Interestingly, six of these deaths (86%) occurred in patients with FLC responses of o90%, while none of the patients judged to have achieved a CR but who had FLC responses of o90% died of progressive amyloid disease (Table 1a) .
Free light-chain responses after SCT in AL amyloidosis V Sanchorawala et al Improvement in amyloid-related organ dysfunction (eg a decrease in proteinuria of 450%) occurred in 96% (26/27) of patients who achieved a hematologic CR compared with 67% (26/39) of patients who did not. However, all patients in the non-CR group with FLC responses of 490% experienced improvements in amyloid-related organ dysfunction after HDM/SCT, compared with 48% of patients (12/25) in the non-CR group with FLC responses of o90% (Table 1b) .
In summary, serum FLC measurements were found to be uninformative in 15% of patients with AL amyloidosis in our study. However, among patients with interpretable elevations in serum FLC levels, decreases of 490% in these levels following HDM/SCT had similar outcomes with respect to survival and clinical improvement, whether or not patients were judged to have achieved a hematologic CR. In contrast, those not achieving a hematologic CR who had FLC responses of o90% were more likely to have inferior clinical outcomes. FLC responses of 450% have been reported to be associated with improved clinical outcomes. 8 However, our results indicate that this measure of hematologic response is a substantially less powerful predictor of clinical benefit than is hematologic CR, as defined by standard criteria. Nonetheless, these measures of hematologic response are clearly complementary. Moreover, quantitative FLC responses (or lack of response) can be detected early following treatment, unlike the qualitative responses determined by IFE and marrow studies that are required to define a CR. We anticipate that prospective studies of FLC responses in future clinical trials of treatment approaches in AL amyloidosis will lead to a clearer understanding of the degree and character of hematologic responses that are associated with meaningful clinical benefit in AL amyloidosis. Free light-chain responses after SCT in AL amyloidosis V Sanchorawala et al
